

CITATION REPORT

List of articles citing

Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial

DOI: 10.1161/01.cir.0000140675.85342.1b
Circulation, 2004, 110, 1202-8.

Source: <https://exaly.com/paper-pdf/36568975/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
729	Platelets in Hematologic and Cardiovascular Disorders: A Clinical Handbook. 2001 ,		2
728	Antiplatelet therapies in cardiology. 2001 , 407-436		
727	Clopidogrel and vascular disease prevention. 2004 , 20, 1835-8		6
726	The value of clopidogrel administered postoperatively following a non-ST-segment elevation acute coronary syndrome. 2005 , 127, 2297		2
725	Aprotinin decreases postoperative bleeding and number of transfusions in patients on clopidogrel undergoing coronary artery bypass graft surgery: a double-blind, placebo-controlled, randomized clinical trial. <i>Circulation</i> , 2005 , 112, 1276-80	16.7	61
724	What is the optimal timing of clopidogrel in acute coronary syndromes?. 2005 , 4, 46-50		7
723	Prognostic Value of Preoperative Cardiac Troponin I in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery. 2005 , 128, 3526-3536		30
722	2005 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations. Part 5: Acute coronary syndromes. 2005 , 67, 249-69		34
721	Estrategia invasiva contemporánea en los pacientes con síndrome coronario agudo sin elevación del segmento ST. 2005 , 5, 26C-39C		
720	Elección del tratamiento antitrombótico en pacientes con síndrome coronario agudo sin elevación del segmento ST de alto riesgo. 2005 , 5, 40C-46C		
719	Clopidogrel en acetylsalicylzuur bij instabiele angina. 2005 , 43, 124-125		
718	The clopidogrel after surgery for coronary artery disease (CASCADE) randomized controlled trial: clopidogrel and aspirin versus aspirin alone after coronary bypass surgery [NCT00228423]. 2005 , 6, 15		28
717	Current awareness: Pharmacoepidemiology and drug safety. 2005 , 14, i-xii		
716	Images in cardiology: Inappropriate pacemaker therapy in congestive heart failure. 2005 , 91, 1140		
715	Clopidogrel in non-ST segment elevation acute coronary syndromes: an overview of the submission by the British Cardiac Society and the Royal College of Physicians of London to the National Institute for Clinical Excellence, and beyond. 2005 , 91, 1135-40		6
714	Part 8: Stabilization of the Patient With Acute Coronary Syndromes. <i>Circulation</i> , 2005 , 112, IV-89-IV-110	16.7	6
713	Is surgery preferred for the diabetic with multivessel disease? Surgery is preferred for the diabetic with multivessel disease. <i>Circulation</i> , 2005 , 112, 1500-7; discussion 1514-5	16.7	26

712	Aspirin and clopidogrel taken until 2 days prior to coronary artery bypass graft surgery is associated with increased postoperative drainage loss. 2005 , 53, 341-5	47
711	Carotid-artery stenting versus endarterectomy. 2005 , 352, 624-7; author reply 624-7	6
710	Recombinant activated factor VII in the management of life-threatening bleeding in cardiac surgery. 2005 , 28, 254-8	37
709	Bisphosphonates as anti-inflammatory agents in ankylosing spondylitis and spondylarthropathies. 2005 , 6, 35-43	13
708	Clopidogrel in acute coronary heart disease. 2005 , 3, 234-42	2
707	Effects of changing clinical practice on costs and outcomes of percutaneous coronary intervention between 1998 and 2002. 2007 , 93, 195-9	3
706	Medications for the treatment of acute coronary syndromes. 2005 , 6, 2843-54	
705	Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. 2005 , 26, 804-47	1159
704	Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. 2005 , 294, 1224-32	521
703	Does clopidogrel improve the long-term outcome after coronary artery bypass surgery?. 2005 , 39, 135-6	2
702	Oral antiplatelet therapy and percutaneous coronary intervention. 2005 , 6, 3-12	3
701	Adding clopidogrel to aspirin improves outcome in ST-elevation myocardial infarction patients receiving fibrinolytic therapy. 2005 , 5, 751-61	3
700	CLARITY about the use of clopidogrel in patients with acute coronary syndromes and myocardial infarction. 2005 , 6, 1761-4	2
699	Balancing the benefit and risk of oral antiplatelet agents in coronary artery bypass surgery. 2005 , 80, 768-79	54
698	Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. 2005 , 150, 1177-84	61
697	[Guidelines for percutaneous coronary interventions]. 2005 , 58, 679-728	19
696	The year in non-ST-segment elevation acute coronary syndromes. 2005 , 46, 906-19	30
695	Application of evidence-based medical therapy is associated with improved outcomes after percutaneous coronary intervention and is a valid quality indicator. 2005 , 46, 1473-8	43

694	Clopidogrel use in coronary artery disease. 2006 , 4, 7-15		4
693	Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes. 2006 , 24, 709-26		15
692	Clopidogrel in the treatment of ischaemic heart disease. 2006 , 7, 1109-20		3
691	Monitoring antiplatelet therapy during peripheral vascular and coronary interventions. 2006 , 9, 56-63		6
690	Non ST segment elevation acute coronary syndromes: A simplified risk-orientated algorithm. 2006 , 22, 663-77		9
689	Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. <i>Circulation</i> , 2006 , 114, 774-82	16.7	1020
688	Newer therapeutic approaches: gout. 2006 , 32, 235-44, xii		17
687	[Prevention of atherothrombotic disease with the combination of two antiplatelet drugs]. 2006 , 127, 153-5		
686	Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery. 2006 , 48, 281-6		159
685	The Reply. 2006 , 119, e7		
684	Double jeopardy: balance between bleeding and stent thrombosis with prolonged dual antiplatelet therapy after drug-eluting stent implantation. 2006 , 7, 155-8		15
683	Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. 2006 , 166, 806-11		44
682	Clopidogrel in non-ST-segment elevation acute coronary syndromes. 2006 , 8, G25-G30		6
681	Clopidogrel (Plavix) Revisited. 2006 , 108, 200-202		
680	Acute Coronary Syndromes Clinical Practice Guidelines. 2006 , 5, 69-102		3
679	Alveolar hemorrhage: an underdiagnosed complication of treatment with glycoprotein IIb/IIIa inhibitors. 2006 , 19, 356-63		25
678	Antithrombotic therapy in cardiac surgery. 2006 , 53, S89-102		20
677	Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. 2006 , 98, 681-4		119

676	Effectiveness of same day percutaneous coronary intervention followed by minimally invasive aortic valve replacement for aortic stenosis and moderate coronary disease ("hybrid approach"). 2006 , 98, 1501-3	52
675	Clopidogrel response variability, resistance, or both?. 2006 , 98, 18N-24N	32
674	Impact of platelet testing on presurgical screening and implications for cardiac and noncardiac surgical procedures. 2006 , 98, 25N-32N	17
673	Estrategia invasiva en el SCASEST. Tratamiento antitrombótico. 2006 , 6, 29H-38H	
672	Interventions to improve guideline compliance following coronary artery bypass grafting. 2006 , 140, 541-7; discussion 547-52	19
671	Management of antiplatelet therapy for minimization of bleeding risk before cardiac surgery. 2006 , 26, 1616-25	4
670	Bleeding and management of bleeding. 2006 , 8, G38-G45	50
669	Combining aspirin with antithrombotic agents. 2006 , 333, 712-3	4
668	Zeit ist Myokard - Frühbehandlung des akuten Koronarsyndroms von besonderer Bedeutung. 2006 , 35, 288-294	
667	[Dual antithrombotic therapy after implantation of coronary stents]. 2006 , 131, 1105-10	3
666	Should high risk patients receive clopidogrel as well as aspirin post coronary arterial bypass grafting?. 2006 , 5, 755-60	6
665	A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension. 2006 , 27, 578-84	44
664	Postoperative clopidogrel improves mid-term outcome after off-pump coronary artery bypass graft surgery: a prospective study. 2006 , 29, 190-5	69
663	Is clopidogrel cardiovascular medicine's double-edged sword?. <i>Circulation</i> , 2006 , 113, 1638-40	16.7 19
662	Should clopidogrel be stopped prior to urgent cardiac surgery?. 2006 , 5, 630-6	14
661	Clopidogrel response variability and future therapies: clopidogrel: does one size fit all?. <i>Circulation</i> , 2006 , 114, e600-6	16.7 93
660	Antiplatelet therapy after percutaneous coronary intervention. 2006 , 21 Suppl 1, 25-34	12
659	Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. 2007 , 28, 1193-204	216

658	Preoperative platelet inhibition with eptifibatid during coronary artery bypass grafting with cardiopulmonary bypass. 2007 , 12, 54-60		9
657	ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction), developed	16.7	927
656	Impact of aspirin with or without clopidogrel on postoperative bleeding and blood transfusion in coronary surgical patients treated prophylactically with a low-dose of aprotinin. 2007 , 28, 1025-32		40
655	Antiplatelet treatment in non-ST-segment elevation acute coronary syndrome patients undergoing percutaneous coronary intervention (ISAR-REACT 2 insight). 2007 , 9, A25-A31		
654	Is clopidogrel associated with poor outcome in patients with non-ST-segment elevation ACS after early CABG surgery?. 2007 , 4, 24-5		2
653	[Dual platelet aggregation inhibition in coronary artery stent implantation--what is evidence-based?]. 2007 , 132, 1275-80		3
652	Platelet-leukocyte interactions in inflammation and atherothrombosis. 2007 , 33, 123-7		60
651	Aktuelle Aspekte der medikamentösen kardiovaskulären Sekundärprävention. 2007 , 3, 190-196		
650	ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/NonST-Elevation Myocardial Infarction: Executive Summary. <i>Circulation</i> , 2007 , 116, 803-877	16.7	158
649	Clopidogrel: an updated and comprehensive review. 2007 , 3, 621-631		16
648	Coronary artery stents and non-cardiac surgery. 2007 , 98, 560-74		98
647	Transfusion practice in coronary artery bypass surgery in Denmark: a multicenter audit. 2007 , 6, 623-7		14
646	Role of clopidogrel in managing atherothrombotic cardiovascular disease. 2007 , 146, 434-41		33
645	Antithrombotic strategies in non-ST elevation acute coronary syndromes: focus on bivalirudin. 2007 , 3, 345-64		6
644	Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. 2007 , CD005158		14
643	Antiplatelet therapy preceding coronary artery surgery: implications for bleeding, transfusion requirements and outcome. 2007 , 24, 332-9		21
642	Antiplatelet therapy in patients undergoing coronary stent implantation: Italian Society of Interventional Cardiology consensus document. 2007 , 8, 782-91		4
641	Effect of Clopidogrel Premedication in Off-Pump Cardiac Surgery: Are We Forfeiting the Benefits of Reduced Hemorrhagic Sequelae?. 2007 , 2007, 264-266		

640	Acute Clopidogrel Use and Outcomes in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery. 2007 , 2007, 236-237	
639	Antiplatelet agents make a comeback in ST-elevation myocardial infarction. 2007 , 154, 603-6	
638	Sex-specific effects of diabetes on adverse outcomes after percutaneous coronary intervention: trends over time. 2007 , 153, 970-8	16
637	Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs. 2007 , 154, 3-11	86
636	Predictors and outcomes of coronary artery bypass grafting in ST elevation myocardial infarction. 2007 , 84, 17-24	50
635	Pro: continuation of aspirin/clopidogrel for cardiac surgery. 2007 , 21, 602-5	1
634	Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. 2007 , 28, 1598-660	1438
633	The role of clopidogrel in revascularized and nonrevascularized patients with acute coronary syndromes. 2007 , 7, 159-68	4
632	Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials. 2007 , 7, 289-97	46
631	Bronchoscopie souple et antiagrégants plaquettaires : analyse du rapport bénéfices-risques. 2007 , 24, 48-56	3
630	Management of non-ST-Segment Elevation Myocardial Infarction. 2007 , 91, 683-700; xi	2
629	[Oral antiagregant drugs in peroperative period. To be maintained or to be removed?]. 2007 , 128, 674-5	2
628	Guía de Práctica Clínica para el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST. 2007 , 60, 1070.e1-1070.e80	14
627	Clopidogrel: a review of its use in the prevention of thrombosis. 2007 , 67, 613-46	50
626	Clopidogrel resistance. 2007 , 16 Suppl 3, S17-28	18
625	ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed	1412
624	ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction Executive Summary. 2007 , 50, 652-726	216
623	Prasugrel versus clopidogrel in patients with acute coronary syndromes. 2007 , 357, 2001-15	4824

622	Pharmacologic Options for Treatment of Ischemic Disease. 2007 , 77-120	0
621	Unstable Angina and Non-ST Elevation Myocardial Infarction. 2007 , 51-81	
620	Perioperative complications in patients with drug-eluting stents: a three-year audit at Geelong Hospital. 2007 , 35, 939-44	14
619	. 2007 ,	1
618	Thienopyridines □ Ticlopidine and Clopidogrel. 37-75	
617	Antithrombotic prevention in vascular disease: bases for a new strategy in antithrombotic therapy. 2007 , 5, 11	2
616	Clopidogrel in Orthopaedic patients: a review of current practice in Scotland. 2007 , 5, 6	21
615	Normalization of platelet reactivity in clopidogrel-treated subjects. 2007 , 5, 82-90	138
614	Approach to the diagnosis and management of mild bleeding disorders. 2007 , 5 Suppl 1, 167-74	49
613	Clopidogrel is safe early after on- and off-pump coronary artery bypass surgery. 2007 , 22, 493-7	17
612	Non-ST segment elevation acute coronary syndromes: treatment guidelines for the nurse practitioner. 2007 , 19, 277-89	1
611	Antiplatelet therapy in patients with unstable angina and non-ST-segment-elevation myocardial infarction: findings from the CRUSADE national quality improvement initiative. 2007 , 27, 1145-62	22
610	The use of clopidogrel in carotid endarterectomy: an audit of current practice. 2007 , 34, 312-3	11
609	Carotid artery stenting in a single center: are six years of experience enough to achieve the standard of care?. 2007 , 34, 655-62	27
608	[Influence of percutaneous coronary intervention in non ST-elevation acute coronary syndromes on prescription of secondary prevention medications. Data from the S-Trein Registry]. 2007 , 56, 30-5	1
607	Effects of preoperative aspirin and clopidogrel therapy on perioperative blood loss and blood transfusion requirements in patients undergoing off-pump coronary artery bypass graft surgery. 2007 , 134, 59-64	53
606	New antiplatelet therapies for acute coronary syndromes. <i>Current Cardiology Reports</i> , 2007 , 9, 303-11	4.2 4
605	Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28. 2007 , 24, 85-91	35

604	Frühe Antiplatelettherapie und Gerinnungshemmung bei akutem Koronarsyndrom. 2007 , 10, 500-510	
603	Clopidogrel and risk for acute coronary events. 2007 , 9, 401-8	5
602	Intensive management of risk factors for accelerated atherosclerosis: the role of multiple interventions. 2007 , 7, 42-8	25
601	Antithrombotische Therapie. 2008 , 4, 435-439	
600	Prevalence, predictors, and impact of conservative medical management for patients with non-ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease. 2008 , 1, 369-78	42
599	Managing antiplatelet therapy in the ACS patient: straight from the emergency department to you. 2008 , 3 Suppl 2, S15-9	
598	Clopidogrel-associated bleeding and related complications in patients undergoing coronary artery bypass grafting. 2008 , 28, 376-92	65
597	The editor's roundtable: management and treatment of non-ST-segment elevation in acute coronary syndromes. 2008 , 101, 1580-98	1
596	Patterns of upstream antiplatelet therapy use before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction (from the CRUSADE National Quality Improvement Initiative). 2008 , 102, 1335-40	7
595	Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. 2008 , 7, 494-9	218
594	Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. 2008 , 51, 690-7	381
593	Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis. 2008 , 52, 1693-701	160
592	Bleeding events with antithrombotic therapy in patients with unstable angina or non-ST-segment elevation myocardial infarction; insights from a large clinical practice registry (GRACE). 2008 , 17, 5-8	4
591	Análisis crítico de ensayos clínicos. ¿Es oro todo lo que reluce?. 2008 , 25, 52-60	
590	Antiplatelet therapy in acute coronary syndromes: the emergency physician's perspective. 2008 , 35, 5-13	10
589	Antiplatelet therapy in acute coronary syndrome: not as confusing as you think. 2008 , 35, 87-90	1
588	Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy. 2008 , 155, 239-44	7
587	Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use. 2008 , 155, 910-7	35

586	Clopidogrel use and bleeding after coronary artery bypass graft surgery. 2008 , 156, 886-92	81
585	Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. 2008 , 156, 1080-1088.e1	117
584	A review of recent developments in the management of carotid artery stenosis. 2008 , 22, 277-89	5
583	Análisis crítico de ensayos clínicos. ¿Es oro todo lo que reluce?. 2008 , 25, 52-60	0
582	Acute myocardial infarction. 2008 , 372, 570-84	466
581	The clinical application of clopidogrel in current coronary artery surgery. 2008 , 22, 329-334	
580	Guideline on antiplatelet and anticoagulation management in cardiac surgery. 2008 , 34, 73-92	230
579	Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. 2009 , 36, 426-35	153
578	Prevention of thrombosis in polycythemia vera and essential thrombocythemia. 2008 , 93, 331-5	33
577	Effect of clopidogrel on bleeding and transfusions after off-pump coronary artery bypass graft surgery: impact of discontinuation prior to surgery. 2008 , 34, 127-31	64
576	Optimizing platelet inhibition. 2008 , 10, D23-D29	12
575	Consensus document on antithrombotic therapy in the setting of electrophysiological procedures. 2008 , 10, 513-27	41
574	Antiplatelet therapy in early management of non-ST-segment elevation acute coronary syndrome: the 2002 and 2007 guidelines from North America and Europe. 2008 , 51, 425-33	4
573	A systematic review of outcomes in patients with staged carotid artery stenting and coronary artery bypass graft surgery. 2008 , 39, 361-5	42
572	Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. 2008 , 29, 2909-45	1774
571	Impact of pretreatment with clopidogrel on initial patency and outcome in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a systematic review. <i>Circulation</i> , 2008 , 118, 1828-36	16.7 64
570	Prescribing practice of general practitioners in Northern Ireland for peripheral arterial disease. 2008 , 59, 57-63	4
569	Preoperative evaluation of patients with neurological disease. 2008 , 28, 603-10	29

568	Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent. 2008 , 34, 93-108	58
567	Emergency medical services management of ST-elevation myocardial infarction. 2008 , 12, 395-403	10
566	New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 2008 , 133, 234S-256S	186
565	Antiplatelet Therapy in Acute Coronary Syndrome without ST Elevation. 143-163	
564	Antiplatelet Therapy in ST-Elevation Myocardial Infarction. 164-177	
563	Antiplatelet Therapy and Coronary Bypass Surgery: Risks and Benefits. 231-250	
562	Unmet needs in antiplatelet therapy. 2008 , 10, D3-D11	5
561	Resistance to aspirin and thienopyridines in diabetes mellitus and metabolic syndrome. 2008 , 6, 313-28	26
560	Antiplatelet and anticoagulant agents: key differences in mechanisms of action, clinical application, and therapeutic benefit in patients with non-ST-segment-elevation acute coronary syndromes. 2008 , 23, 302-8	7
559	The risk of iatrogenic bleeding in acute coronary syndromes and long-term mortality. 2008 , 23, 327-34	14
558	Coronary artery stents: II. Perioperative considerations and management. 2008 , 107, 570-90	87
557	Point-of-care whole blood impedance aggregometry versus classical light transmission aggregometry for detecting aspirin and clopidogrel: the results of a pilot study. 2008 , 107, 1798-806	97
556	Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) unstable angina/non-ST elevation myocardial infarction critical pathway toolkit. 2008 , 7, 43-81	6
555	. 2008 ,	8
554	. 2008 ,	1
553	Effect of Low-dose, Enteric Coated Aspirin on Gastrointestinal Bleeding in Patients with Coronary Artery Disease. 2008 , 2, 99-104	3
552	Acute Coronary Syndromes and Acute Myocardial Infarction. 2008 , 589-646	
551	Antiplatelet medications in hemodialysis patients: a systematic review of bleeding rates. 2009 , 4, 1347-55	55

550	Reoperation for bleeding in patients undergoing coronary artery bypass surgery: incidence, risk factors, time trends, and outcomes. 2009 , 2, 583-90		125
549	An assessment of cardiopulmonary bypass-induced changes in platelet function using whole blood and classical light transmission aggregometry: the results of a pilot study. 2009 , 108, 1747-54		69
548	Pharmacogenetics in hemostasis: friend or foe?. 2009 , 35, 42-9		4
547	Evaluation of hospitalization and follow-up care costs among patients hospitalized with ACS treated with a stent and clopidogrel. 2009 , 25, 2845-52		3
546	Perioperative management of patients on adenosine diphosphate inhibitors in the era of drug-eluting stents: review of the literature and clinical implications. 2009 , 16, 591-8		2
545	Leitfaden Herzkatheter. 2009 ,		2
544	Reply to Colli and Mestres. Controversial issues regarding aspirin and clopidogrel therapy for patients after cardiac surgery. 2009 , 35, 197-198		
543	Use of aspirin versus clopidogrel plus aspirin after coronary artery bypass graft surgery. 2009 , 15, 540-4		12
542	Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. <i>Circulation</i> , 2009 , 119, 1634-42	16.7	166
541	Avoiding and managing bleeding complications in patients with non-ST-segment elevation acute coronary syndromes. 2009 , 60, 148-58		1
540	EACTS guideline on antiplatelet and anticoagulation management in cardiac surgery. 2009 , 35, 197; author reply 197-8		
539	Antiplatelet agents used for early intervention in acute coronary syndrome: myocardial salvage versus bleeding complications. 2009 , 138, 807-10		12
538	Aspirin and clopidogrel use in the early postoperative period following on-pump and off-pump coronary artery bypass grafting. 2009 , 138, 1377-84		48
537	Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease. 2009 , 29, 812-21		10
536	Evidence for using clopidogrel alone or in addition to aspirin in post coronary artery bypass surgery patients. 2009 , 103, 1687-93		24
535	Platelet-directed therapies and coronary artery bypass grafting. 2009 , 104, 44C-8C		10
534	Strategies to reduce bleeding among patients with ischemic heart disease treated with antiplatelet therapies. 2009 , 104, 60C-3C		9
533	How to manage patients with need for antiplatelet therapy in the setting of (un-)planned surgery. 2009 , 98, 8-15		21

532	Kommentar zu den Leitlinien der European Society of Cardiology (ESC) zur Diagnose und Therapie des akuten Koronarsyndroms ohne ST-Strecken-Hebung (NSTEMI-ACS). 2009 , 3, 81-100	11
531	Thienopyridine therapy and risk for cardiovascular events in secondary prevention. 2009 , 11, 364-70	3
530	Contemporary issues on clopidogrel therapy. 2009 , 4, 201-11	1
529	[Acute coronary syndromes without ST segment elevation]. 2009 , 34, 30-8	0
528	Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial. 2009 , 63, 667-70	11
527	Unmet needs in oral antiplatelet therapy with ADP receptor blocking agents. 2009 , 23, 1-9	6
526	Variability of response to antiplatelet therapy: what should we do next?. 2009 , 23, 19-22	1
525	Antiplatelet therapy and coronary artery bypass graft surgery: perioperative safety and efficacy. 2009 , 8, 169-82	41
524	Biological and pharmacological aspects of perioperative hemorrhagic complications associated with oral platelet-directed antithrombotic agents. Focus on isolated coronary artery bypass grafting and oral irreversible P2Y(12) receptor antagonists. 2009 , 123, 419-28	3
523	Antiplatelet therapies and the role of antiplatelet resistance in acute coronary syndrome. 2009 , 124, 6-13	39
522	Predictors of long-term use of evidence-based therapies after non-ST-segment elevation acute coronary syndrome. The S-Trein survey. 2009 , 133, 32-40	6
521	Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. 2009 , 157, 369-74	63
520	Facts and controversies of aspirin and clopidogrel therapy. 2009 , 157, 412-22	17
519	Temporal trends and patterns of early clopidogrel use across the spectrum of acute coronary syndromes. 2009 , 157, 642-50.e1	27
518	Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute coronary syndrome patients: the Canadian global registry of acute coronary events (GRACE) experience. 2009 , 158, 917-24	15
517	Abbreviated infusion of eptifibatid after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatid Following Percutaneous Coronary Intervention) randomized trial. 2009 , 53, 837-45	51
516	Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) trial. 2009 , 53, 1965-72	114
515	Reply. 2009 , 54, 90-91	1

514	Ticagrelor versus clopidogrel in patients with acute coronary syndromes. 2009 , 361, 1045-57	4753
513	In-hospital outcomes associated with fibrinolytic and thienopyridine use in patients with ST-segment elevation acute myocardial infarction. The global registry of acute coronary events. 2009 , 62, 501-9	1
512	Clinical outcomes with off-pump coronary surgery after angioplasty with stent. 2009 , 62, 520-7	1
511	Drug-eluting stents for acute myocardial infarction. 2009 , 10, 19-34	2
510	Increased rehospitalization rate after coronary bypass operation for acute coronary syndrome: a prospective study in 200 patients. 2009 , 88, 1148-52	4
509	Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular Society. 2009 , 25, 683-9	63
508	[Not Available]. 2009 , 62, 293.e1-293.e47	5
507	Evoluci3n hospitalaria asociada al empleo de fibrinol3ticos y tienopiridinas en pacientes con infarto agudo de miocardio y elevaci3n del segmento ST. The Global Registry of Acute Coronary Events. 2009 , 62, 501-509	1
506	Resultados de la cirug3a coronaria sin circulaci3n extracorp3rea tras angioplastia con stent. 2009 , 62, 520-527	5
505	[Intraoperative use of activated recombinant factor VII in a patient with brain cancer]. 2009 , 56, 394-6	1
504	Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. 2009 , 20, S240-9	163
503	Clinical implications and management of bleeding events in patients with acute coronary syndromes. 2009 , 10, 677-86	7
502	Coronary bypass surgery in patients treated with clopidogrel. Is it safe?. 2009 , 24, 539-43	2
501	Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice. 2009 , 8, 12-9	3
500	Clopidogrel in the management of acute coronary syndromes: indications, results, obstacles. 2009 , 8, 49-54	1
499	Year 2008 ESC ST-segment elevation myocardial infarction guidelines: implications for the interventional cardiologist—from evidence to recommendations and practice. 2009 , 11, C31-C37	3
498	Antiplatelet Therapy. 2009 , 161-172	
497	Perioperative management of antiplatelet-drugs in cardiac surgery. 2009 , 5, 125-32	15

496	Syndromes coronaires aigus. 2010 , 5, 1-21	
495	Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia. 2010 , 252, 37-42	25
494	The patient with coronary stents and antiplatelet agents: what to do and how to deal?. 2010 , 27, 406-10	6
493	Early antiplatelet therapy in coronary artery bypass grafting: a calculated benefit. 2010 , 5, 317-25	2
492	Rapid change in prescribing behavior in hospitals participating in get with the guidelines-stroke after release of the management of atherothrombosis with clopidogrel in high-risk patients (MATCH) clinical trial results. 2010 , 41, 2094-7	11
491	Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies. 2010 , 103, 535-44	35
490	Safety of dual antiplatelet therapy in daily cardiology practice. 2010 , 18, 228-9	
489	Changes in short- and long-term cardiovascular risk of incident diabetes and incident myocardial infarction--a nationwide study. 2010 , 53, 1612-9	35
488	[STEMI guidelines 2008--Do they influence today's myocardial infarction treatment strategies in rural areas?]. 2010 , 160, 54-60	
487	Antithrombotische Therapie beim ST-Streckenhebungsinfarkt. 2010 , 4, 107-123	6
486	Pharmaka zur Thrombozyten- und Gerinnungshemmung in der Behandlung des akuten Koronarsyndroms. 2010 , 4, 239-248	0
485	Antiplatelet and anticoagulant therapies in acute coronary syndromes. 2010 , 24, 61-70	7
484	Bleeding associated with current therapies for acute coronary syndrome: what are the mechanisms?. 2010 , 30, 332-9	9
483	Estratificaci3n del riesgo hemorr3gico en el s3ndrome coronario agudo. 2010 , 10, 49-58	
482	Efficacy of high-dose clopidogrel treatment (600 mg) less than two hours before percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes. 2010 , 105, 323-32	20
481	Controversies in oral antiplatelet therapy in patients undergoing aortocoronary bypass surgery. 2010 , 90, 1040-51	22
480	Antiplatelet agents in acute coronary syndromes. 2010 , 35, 123-70	13
479	Perioperative management of patients with drug-eluting stents. 2010 , 3, 131-42	59

478	Management of acute coronary syndrome in a tertiary care general medical unit in Sri Lanka: how closely do we follow the guidelines?. 2010 , 35, 421-7		5
477	Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome. 2010 , 6, 963-77		19
476	Role of TGF-beta1 and MAP kinases in the antiproliferative effect of aspirin in human vascular smooth muscle cells. 2010 , 5, e9800		8
475	Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update. 2010 , 6, 855-67		9
474	Review of isolated systolic hypertension in older adults. 2010 , 25, 374-8		1
473	Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial. <i>Circulation</i> , 2010 , 122, 2680-7	16.7	149
472	Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). 2010 , 35, 64-101		885
471	Prasugrel: an efficacy and safety review of a new antiplatelet therapy option. 2010 , 9, 199-202		2
470	Clinical pharmacology: antiplatelet therapy during surgery. 2010 , 96, 986-91		18
469	Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. 2010 , 104, 285-91		157
468	Perioperative assessment of platelet function in patients under antiplatelet therapy. 2010 , 7, 625-37		16
467	Part 10: acute coronary syndromes: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i> , 2010 , 122, S787-817	16.7	191
466	Modified thromboelastography evaluation of platelet dysfunction in patients undergoing coronary artery surgery. 2010 , 37, 1367-74		55
465	Three-vessel coronary disease in diabetics: personalized versus evidence-based revascularization strategy. 2010 , 6, 797-809		2
464	Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. 2010 , 363, 930-42		582
463	Médicaments antiplaquettaires: anciennes et nouvelles thérapies. 2010 , 24, 154-163		
462	Antiplatelet medications: old and emerging therapies. 2010 , 24, 140-8		2
461	Secondary stroke prevention. 2010 , 6, 477-86		21

460	Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery a single-center, randomized, controlled trial. 2010 , 56, 1639-43	128
459	Clopidogrel responsiveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after off-pump coronary artery bypass graft surgery. 2010 , 56, 1994-2002	104
458	Examining treatment of ST-elevation myocardial infarction: the importance of early intervention. 2010 , 15, 6-16	9
457	Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. <i>Circulation</i> , 2010 , 122, 2131-41	16.7 392
456	Optimal pretreatment timing for high load dosing (600 mg) of clopidogrel before planned percutaneous coronary intervention for maximal antiplatelet effectiveness. 2010 , 144, 255-7	12
455	Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medically manage Acute Coronary Syndromes (TRACRYL) trial. 2010 , 140, 1633-4	109
454	Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting study. 2010 , 160, 1178-84	78
453	A risk score to predict bleeding in patients with acute coronary syndromes. 2010 , 55, 2556-66	479
452	Adjunctive Pharmacologic Therapies in Acute Myocardial Infarction. 2010 , 145-182	1
451	Emerging drugs for acute myocardial infarction. 2010 , 15, 87-105	0
450	Synopsis of Adult Cardiac Surgical Disease. 2010 , 1-83	
449	Medium on-treatment platelet reactivity to ADP is favorable in patients with acute coronary syndromes undergoing coronary stenting. 2011 , 22, 521-9	4
448	Ticagrelor. 2011 , 5, 55-62	
447	[Periprocedural management of hemostasis risk in interventional radiology]. 2011 , 92, 659-70	13
446	Uso della doppia terapia aspirina + clopidogrel: rischi in ambito odontoiatrico. 2011 , 79, 63-76	
445	Efficacy of post-operative clopidogrel treatment in patients revascularized with coronary artery bypass grafting after myocardial infarction. 2011 , 57, 1202-9	62
444	Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. 2011 , 57, 672-84	370
443	2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. 2011 , 57, e215-367	338

442	Clopidogrel after coronary artery bypass graft surgery: insufficient evidence. 2011 , 58, 1084-5; author reply 1085-6	2
441	Reply. 2011 , 58, 1085-1086	1
440	2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. 2011 , 58, e123-210	531
439	Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. 2011 , CD005158	19
438	Managing adverse effects and drug-drug interactions of antiplatelet agents. 2011 , 8, 592-600	15
437	Management of antiplatelet therapy inpatients at risk for coronary StentThrombosis undergoing non-cardiac surgery. 2011 , 71, 1797-806	6
436	Hypercoagulable state after off-pump coronary artery bypass grafting: evidence, mechanisms and implications. 2011 , 9, 599-608	9
435	Clopidogrel loading dose and bleeding outcomes in patients undergoing urgent coronary artery bypass grafting. 2011 , 161, 404-10	20
434	Early clopidogrel use in non-ST elevation acute coronary syndrome and subsequent coronary artery bypass grafting. 2011 , 161, 832-41	16
433	The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines. 2011 , 27 Suppl A, S1-59	85
432	The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society Guidelines Executive Summary. 2011 , 27, 208-21	39
431	Use of clopidogrel post-coronary artery bypass surgery in canadian patients with acute coronary syndromes. 2011 , 27, 711-5	9
430	Antiplatelet therapy in the perioperative period. 2011 , 22, 26-31	21
429	Complications of cutaneous surgery in patients taking clopidogrel-containing anticoagulation. 2011 , 65, 584-591	48
428	Focused clinical review: periprocedural management of antiplatelet therapy in patients with coronary stents. 2011 , 20, 438-45	7
427	Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease. 2011 , 54, e1-31	439
426	Acute multi-vessel coronary stent thrombosis. 2011 , 41, e43-8	1
425	ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). 2011 , 38, 2868-3054	2614

424	Therapeutic strategies in patients with chronic stable coronary artery disease. 2011 , 29, e23-30	3
423	THERAPEUTIC EQUIVALENCE OF ORIGINAL CLOPIDOGREL (PLAVIX) AND ITS GENERIC (EGITROMB). RESULTS OF COMPARATIVE RANDOMIZED CROSS-OVER BLIND STUDY. 2011, 7, 19-25	
422	Role of newly formed platelets in thrombus formation in rat after clopidogrel treatment: comparison to the reversible binding P2Y ₁₂ antagonist ticagrelor. 2011 , 106, 1179-88	12
421	Peri-operative platelet function testing: the potential for reducing ischaemic and bleeding risks. 2011, 106, 248-52	23
420	Cardiac protection and pharmacologic management of myocardial ischemia. 1091-1105	
419	Editorial: do we need another bleeding definition? What does the Bleeding Academic Research Consortium definition have to offer?. 2011 , 26, 275-8	4
418	Emergency cardiac surgery in patients with acute coronary syndromes: a review of the evidence and perioperative implications of medical and mechanical therapeutics. 2011 , 112, 777-99	15
417	Antiplatelet therapy in acute coronary syndromes: implications for nursing practice. 2011 , 26, 239-49	2
416	Effect of hydroxyethyl starch 130/0.4 on blood loss and coagulation in patients with recent exposure to dual antiplatelet therapy undergoing off-pump coronary artery bypass graft surgery. 2011 , 75, 2397-402	29
415	Cessation of clopidogrel before major abdominal procedures. 2011 , 146, 334-9	32
414	Anti-platelet therapy: ADP receptor antagonists. 2011 , 72, 647-57	71
413	How do we manage patients treated with antithrombotic therapy in the perioperative interval. 2011 , 51, 2066-77	5
412	Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses. 2011 , 9, 1730-7	41
411	Management of patients with recently implanted coronary stents on dual antiplatelet therapy who need to undergo major surgery. 2011 , 9, 2133-42	68
410	L'offre antiplaquettaire s'élève. 2011 , 22, 14-15	
409	An early and simple predictor of severe left main and/or three-vessel disease in patients with non-ST-segment elevation acute coronary syndrome. 2011 , 107, 495-500	54
408	Assessing the risk of clopidogrel-related bleeding complications in patients undergoing inguinal herniorrhaphy. 2011 , 15, 31-5	16
407	P2Y ₁₂ antagonists in acute coronary syndrome: in whom should they be started, and when?. <i>Current Cardiology Reports</i> , 2011 , 13, 320-6	4.2 1

406	Secondary stroke prevention in women. 2011 , 7, 391-7		2
405	Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation: a review of the current guidelines and literature. 2011 , 39, 32-40		10
404	Does Platelet Function Testing Predict Bleeding?-Pro. 2011 , 10, 133-135		
403	Triple antithrombotic therapy after coronary stenting: why expert opinion is necessary. 2011 , 4, 410-2		
402	2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i> , 2011 , 124, e652-735	16.7	487
401	Determination of residual antiplatelet activity of clopidogrel before neuraxial injections. 2011 , 107, 966-71		21
400	Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies. 2011 , 32, 2970-88		71
399	2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i> , 2011 , 123, e426-579	16.7	365
398	Prevalence, predictors, and outcomes of conservative medical management in non-ST-segment elevation acute coronary syndromes in Gulf RACE-2. 2012 , 63, 109-18		11
397	Reply to Petricevic et al.. 2012 , 42, 761-761		
396	Bleeding complications in patients with acute coronary syndromes: are they important and how can we prevent them?. 2012 , 40, 96-103		
395	Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. 2012 , 307, 265-74		329
394	Recommendations for management of antiplatelet therapy in patients undergoing elective noncardiac surgery after coronary stent implantation. 2012 , 11, 177-85		17
393	Lessons from platelet inhibition and patient outcomes. 2012 , 27, 355-60		
392	Interventionelle Strategie beim NSTEMI-ACS Diagnostik, Risikoabschätzung und optimale Intervention. 2012 , 41, 542-545		
391	Perioperative management of patients having noncardiac surgery who are receiving anticoagulant or antiplatelet therapy: an evidence-based but practical approach. 2012 , 38, 652-60		13
390	Risk of bleeding related to antithrombotic treatment in cardiovascular disease. 2012 , 18, 5362-78		5
389	Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary artery bypaSS occlusion After off-pump procedures) randomised study. 2012 , 98, 1710-5		98

388	Antiplatelet efficacy of long-term treatment with clopidogrel besylate in patients with a history of acute coronary syndrome: comparison with clopidogrel hydrogen sulfate. 2012 , 63, 547-51	7
387	Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study. 2012 , 5, 261-9	196
386	Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention. 2012 , 40, 104-17	1
385	Impact of aspirin resistance on antiplatelet therapy management after coronary artery surgery. 2012 , 42, 760-1; author reply 761	4
384	Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 2012 , 141, e326S-e350S	1175
383	Stent-assisted coiling of wide-necked aneurysms in the setting of acute subarachnoid hemorrhage: experience in 65 patients. 2012 , 70, 1415-29; discussion 1429	89
382	Pre-hospital versus in-hospital thrombolysis for acute myocardial infarction. 2012 ,	
381	Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 2012 , 141, e637S-e668S	371
380	Perioperative management of antiplatelet agents in patients undergoing cardiac surgery. 2012 , 26, 680-6	7
379	2012 update to the Society of Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations. 2012 , 94, 1761-81	221
378	Use of aspirin and clopidogrel after coronary artery bypass graft surgery. 2012 , 46, 678-87	23
377	Clopidogrel and cardiac surgery: enemy or friend?. 2012 , 98, 1685-6	2
376	Bleeding and the use of antiplatelet agents in the management of acute coronary syndromes and atrial fibrillation. 2012 , 47, 125-40	
375	Is chest tube insertion with ultrasound guidance safe in patients using clopidogrel?. 2012 , 17, 1222-4	17
374	Cardiac dysfunction in the CABG patient. 2012 , 12, 166-71	14
373	Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. 2012 , 23, 727-36	452
372	Risk factors for re-exploration due to bleeding after coronary artery bypass grafting. 2012 , 46, 39-44	8
371	Correlation between point-of-care platelet function testing and bleeding after coronary artery surgery. 2012 , 46, 32-8	20

- 370 [Myocardial revascularization]. **2012**, 53, 1063-75; quiz 1076-8 1
- 369 Guía de práctica clínica de la ESC para el manejo del síndrome coronario agudo en pacientes sin elevación persistente del segmento ST. **2012**, 65, 173.e1-173.e55 15
- 368 Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. **2012**, 163, 182-90.e4 83
- 367 Triple antithrombotic therapy after coronary stenting in the elderly with atrial fibrillation: necessary or too hazardous?. **2012**, 163, 531-4 3
- 366 Characteristics and in-hospital outcomes of patients presenting with non-ST-segment elevation myocardial infarction found to have significant coronary artery disease on coronary angiography and managed medically: stratification according to renal function. **2012**, 164, 52-7.e1 15
- 365 Preoperative thienopyridine use and outcomes after surgery: a systematic review. **2012**, 125, 87-99.e1 11
- 364 Thrombelastographic haemostatic status and antiplatelet therapy after coronary artery bypass surgery (TEG-CABG trial): assessing and monitoring the antithrombotic effect of clopidogrel and aspirin versus aspirin alone in hypercoagulable patients: study protocol for a randomized controlled trial. **2012**, 13, 48 13
- 363 Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus. **2012**, 11, CD005449 7
- 362 Acute coronary syndromes: considerations for improved acceptance and implementation of management guidelines. **2012**, 10, 489-503 10
- 361 Stent thrombosis in patients with chronic kidney disease. **2012**, 10, 617-26
- 360 Ticagrelor: molecular discovery to clinical evidence: ticagrelor: a novel antiplatelet agent. **2012**, 64, 497-502 7
- 359 Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. **2012**, 60, 388-96 146
- 358 InforMatrix: ADP antagonists in acute coronary syndromes. **2012**, 13, 357-85
- 357 Clinical use of aspirin in treatment and prevention of cardiovascular disease. **2012**, 2012, 245037 42
- 356 The avantgarde carbostent in patients scheduled for undelayable noncardiac surgery. **2012**, 2012, 372371 2
- 355 Clopidogrel trial in patients with elective percutaneous coronary intervention for stable angina and old myocardial infarction (CLEAN). **2012**, 53, 91-101 6
- 354 Does Dual Antiplatelet Therapy Affect Blood Loss and Transfusion Requirements in Robotic-Assisted Coronary Artery Surgery?. **2012**, 7, 399-402 12
- 353 Platelet Function after Cessation of Chronic Clopidogrel Therapy. **2012**, 78, 51-56 5

352	ALTERNATIVE APPROACHES TO THE USE OF TWO COMPONENT ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME: EVIDENCES, RECOMMENDATIONS AND REAL PRACTICE. 2012 , 8, 531-537	
351	Diagnosis and treatment of platelet hyperactivity in relation to thrombosis in dogs and cats. 2012 , 22, 42-58	9
350	Improving long-term ACS management: is there a role for the new antiplatelets?. 2012 , 25, 425-32	1
349	Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies. 2012 , 143, 665-675.e4	74
348	Non-ST-segment elevation acute coronary syndrome presenting with ST-segment elevation in aVR and dual antiplatelet therapy. 2012 , 45, 283-4	
347	Use of evidence-based therapy for the secondary prevention of acute coronary syndromes in Malaysian practice. 2013 , 19, 658-63	9
346	Relationship between postoperative clopidogrel use and subsequent angiographic and clinical outcomes following coronary artery bypass grafting. 2013 , 36, 384-93	10
345	Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis. 2013 , 36, 223-32	29
344	Refining the role of antiplatelet therapy in medically managed patients with acute coronary syndrome. 2013 , 111, 439-44	8
343	[Myocardial revascularization]. 2013 , 38, 513-26; quiz 527-8	
342	Time from adenosine di-phosphate receptor antagonist discontinuation to coronary bypass surgery in patients with acute coronary syndrome: meta-analysis and meta-regression. 2013 , 168, 1955-64	19
341	The prevalence of malignant neoplastic and non-malignant gastrointestinal lesions in cardiology inpatients. 2013 , 61, 181-5	6
340	Prevalence, indications and appropriateness of antiplatelet therapy in patients operated for acute aortic dissection: associations with bleeding complications and mortality. 2013 , 99, 116-21	28
339	Optimal treatment of ACS patients: issues and considerations for upstream antiplatelet therapy. 2013 , 163, 19-25	2
338	Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: insights from the PLATelet inhibition and patient outcomes (PLATO) trial. 2013 , 166, 474-80	27
337	Antiplatelet therapy at the time of coronary artery bypass grafting: a multicentre cohort study. 2013 , 44, e133-40	32
336	The pharmacokinetics and safety of a fixed-dose combination of acetylsalicylic acid and clopidogrel compared with the concurrent administration of acetylsalicylic acid and clopidogrel in healthy subjects: a randomized, open-label, 2-sequence, 2-period, single-dose crossover study. 2013 , 35, 985-94	10
335	A critical overview on ticagrelor in acute coronary syndromes. 2013 , 106, 105-15	15

334	Management of antiplatelet therapy in patients with coronary artery disease requiring cardiac and noncardiac surgery. <i>Circulation</i> , 2013 , 128, 2785-98	16.7	73
333	Meta-analysis of effect of single versus dual antiplatelet therapy on early patency of bypass conduits after coronary artery bypass grafting. 2013 , 112, 1576-9		52
332	Antiplatelet therapy: aspirin resistance and all that jazz!. 2013 , 19, 5-18		10
331	Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. <i>Circulation</i> , 2013 , 127, 634-40	16.7	387
330	2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 , 61, e179-347		328
329	ED administration of thienopyridines in non-ST-segment elevation myocardial infarction: results from the NCDR. 2013 , 31, 1005-11		3
328	Síndrome coronario agudo con y sin elevaci3n del segmento ST: ¿c3mo darles igualdad de oportunidades?. 2013 , 13, 24-28		
327	Tranexamic Acid in on-pump coronary artery bypass grafting without clopidogrel and aspirin cessation: randomized trial and 1-year follow-up. 2013 , 95, 795-802		24
326	Upstream antiactivation antiplatelet therapy: first, do no harm. Then consider doing some good. 2013 , 31, 1408-9		1
325	Enfermedad coronaria aguda y cr3nica. ¿C3mo tratamos los diferentes subgrupos?. 2013 , 13, 29-34		
324	Addendum of newer anticoagulants to the SIR consensus guideline. 2013 , 24, 641-5		93
323	Endovascular treatment of aneurisms: pre, intra and post operative management. 2013 , 82, 1633-7		13
322	Protective effects of tranexamic acid on clopidogrel before coronary artery bypass grafting: a multicenter randomized trial. 2013 , 148, 538-47		32
321	Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. 2013 , 29, 1334-45		81
320	Adherence to dual antiplatelet therapy: can we do better?. 2013 , 11, 1417-24		3
319	2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i> , 2013 , 127, e663-828	16.7	193
318	Coronary artery stents and surgery; the basis of sound perioperative management. 2013 , 05, 1730-1736		2
317	Dual antiplatelet therapy with aspirin and clopidogrel: what is the risk in noncardiac surgery? A narrative review. 2013 , 41, 79-88		10

316	Combined clopidogrel and aspirin treatment up to surgery increases the risk of postoperative myocardial infarction, blood loss and reoperation for bleeding in patients undergoing coronary artery bypass grafting. 2013 , 43, 722-8	37
315	Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism. 2013 , 112, 174-94	34
314	Percutaneous dilational tracheostomy in patients receiving antiplatelet therapy: is it safe?. 2013 , 20, 322-5	11
313	Antithrombotic therapy during and after percutaneous coronary intervention in patients with atrial fibrillation. <i>Circulation</i> , 2013 , 128, 2058-61	16.7 4
312	Novel direct-acting anticoagulants for risk reduction in ACS. 2013 , 26, 358-66	2
311	Novel antiplatelet agent use for acute coronary syndrome in the emergency department: a review. 2013 , 2013, 127270	5
310	Impact and Diagnosis of Antiplatelet Therapy Resistance in Patients Undergoing Cardiac Surgery. 2013 , 74, 492-504	1
309	Long-term effect of dual antiplatelet treatment after off-pump coronary artery bypass grafting. 2013 , 28, 366-72	16
308	Guidelines for the clinical application of bypass grafts and the surgical techniques (JCS 2011) published in 2012--digest version. 2013 , 77, 1608-41	5
307	Perioperative management of antiplatelet therapy in patients with a coronary stent who need noncardiac surgery: a systematic review of clinical practice guidelines. 2013 , 144, 1848-1856	51
306	Effect of platelet inhibition on bleeding complications in trauma patients on preinjury clopidogrel. 2013 , 74, 1419-24	7
305	Perioperative handling of antiplatelet drugs. A critical appraisal. 2013 , 14, 880-8	24
304	Optimal anticoagulation during off pump coronary artery bypass in patients recently exposed to clopidogrel. 2013 , 54, 1119-26	6
303	Pulmonary Alveolar Hemorrhage after Clopidogrel Use for ST Elevation Myocardial Infarction. 2013 , 43, 497-9	8
302	Platelet function testing and prediction of procedural bleeding risk. 2013 , 109, 817-24	28
301	Treatment of Coronary Artery Bypass Graft Failure. 2013 ,	3
300	The Antiagregant Treatment After Coronary Artery Surgery Depending on Cost [Benefit Report. 2013 ,	
299	Ticagrelor. 2013 , 55-62	

298	Safety of percutaneous tunneled hemodialysis catheter procedures in patients receiving concurrent clopidogrel therapy. 2014 , 15, 33-7		5
297	Transfusion strategy: impact of haemodynamics and the challenge of haemodilution. 2014 , 2014, 627141		6
296	ANMCO/SICI-GISE paper on antiplatelet therapy in acute coronary syndrome. 2014 , 16, C2-C28		2
295	Pre-hospital versus in-hospital thrombolysis for ST-elevation myocardial infarction. 2014 , CD010191		14
294	Cangrelor for treatment during percutaneous coronary intervention. 2014 , 10, 201-13		1
293	Use of antiplatelet drugs after cardiac operations. 2014 , 26, 223-30		5
292	Pretreatment with P2Y12 inhibitors in non-ST-segment-elevation acute coronary syndrome is clinically justified. <i>Circulation</i> , 2014 , 130, 1891-903; discussion 1903	16.7	36
291	Estimating the effects of time-varying exposures in observational studies using Cox models with stabilized weights adjustment. 2014 , 23, 812-8		6
290	¿Por qué debemos estratificar el riesgo hemorrágico junto con el isquémico en el síndrome coronario agudo?. 2014 , 14, 10-17		
289	2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i> , 2014 , 130, e344-426	16.7	754
288	Perspectives on the management of antiplatelet therapy in patients with coronary artery disease requiring cardiac and noncardiac surgery. 2014 , 29, 553-63		8
287	A new reversible and potent P2Y12 receptor antagonist (ACT-246475): tolerability, pharmacokinetics, and pharmacodynamics in a first-in-man trial. 2014 , 34, 807-18		22
286	Bridging antiplatelet therapy in patients requiring cardiac and non-cardiac surgery: from bench to bedside. 2014 , 7, 82-90		5
285	New antiplatelet agents in the treatment of acute coronary syndromes. 2014 , 107, 178-87		11
284	Toxin-induced coagulopathy. 2014 , 32, 53-78		2
283	Recomendações da SBA para segurança na anestesia regional em uso de anticoagulantes. 2014 , 64, 1-15		4
282	Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. <i>Circulation</i> , 2014 , 129, 1577-85	16.7	204
281	Optimization of 2-phenyl-pyrimidine-4-carboxamides towards potent, orally bioavailable and selective P2Y(12) antagonists for inhibition of platelet aggregation. 2014 , 24, 4323-31		22

280	Sources of hospital-level variation in major bleeding among patients with non-st-segment elevation myocardial infarction: a report from the National Cardiovascular Data Registry (NCDR). 2014 , 7, 236-43	6
279	2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 , 64, e139-e228	1822
278	Japanese postmarketing surveillance of clopidogrel for patients with non-ST-segment-elevation acute coronary syndrome indicated for percutaneous coronary intervention (J-PLACE NSTE-ACS). 2014 , 29, 123-33	2
277	Effect of clopidogrel use post coronary artery bypass surgery on graft patency. 2014 , 97, 15-21	32
276	Individualized strategy for clopidogrel suspension in patients undergoing off-pump coronary surgery for acute coronary syndrome: a case-control study. 2014 , 148, 1299-306	23
275	Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting. 2014 , 113, 1660-7	35
274	Recomendaciones de SBA para la seguridad en la anestesia regional en uso de anticoagulantes. 2014 , 64, 1-15	
273	SBA recommendations for regional anesthesia safety in patients taking anticoagulants. 2014 , 64, 1-15	2
272	Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). 2014 , 63, 1048-57	38
271	Adenosine diphosphate-induced single-platelet count aggregation and bleeding in clopidogrel-treated patients undergoing coronary artery bypass grafting. 2014 , 28, 230-4	11
270	Acute coronary syndrome antiplatelet alternatives in clopidogrel allergy. 2014 , 34, e152-6	7
269	Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery. 2014 , 35, 1510-4	58
268	Dual antiplatelet therapy in patients with acute coronary syndrome treated by surgical revascularization. 2014 , 56, e246-e253	
267	Should clopidogrel be discontinued before coronary artery bypass grafting for patients with acute coronary syndrome? A systematic review and meta-analysis. 2014 , 148, 3092-8	27
266	Preoperative fibrinogen and morbidity in patients with residual platelet inhibition undergoing off-pump coronary artery bypass grafting: cause or effect?. 2014 , 78, 1571-3	
265	Perioperative Thrombozytenaggregationshemmung und Antikoagulation in der Herzchirurgie. 2014 , 3, 93-98	
264	Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications: guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the	183
263	Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials. <i>BMC Surgery</i> , 2015 , 15, 112	2.3 52

262	Triple therapy for percutaneous coronary intervention in atrial fibrillation: standard of care, or a nightmare soon to end?. 2015 , 13 Suppl 1, S332-5		2
261	Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry. 2015 , 113, 272-82		33
260	Does Preoperative Platelet Function Predict Bleeding in Patients Undergoing Off Pump Coronary Artery Bypass Surgery?. 2015 , 28, 223-32		17
259	Outcomes of preoperative bridging therapy for patients undergoing surgery after coronary stent implantation: a weighted meta-analysis of 280 patients from eight studies. 2015 , 85, 25-31		31
258	Efficacy and Safety of Intracoronary versus Intravenous Administration of Tirofiban during Percutaneous Coronary Intervention for Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials. 2015 , 10, e0129718		5
257	Peripherally inserted central catheter placement in patients with coagulation disorders: A retrospective analysis. 2015 , 96, 1147-51		10
256	Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study. 2015 , 8, e002786		47
255	Economic outcomes with prasugrel versus clopidogrel in acute coronary syndrome patients: observations from prasugrel users and matched clopidogrel users. 2015 , 18, 1074-84		
254	Current strategies for bridging dual antiplatelet therapy in patients requiring surgery. 2015 , 7, 137-148		2
253	Feasibility and Early Safety of Single-Stage Hybrid Coronary Intervention and Valvular Cardiac Surgery. 2015 , 99, 2032-7		12
252	Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. <i>Circulation</i> , 2015 , 131, 927-64	16.7	226
251	Reporting of adverse events in surgical trials: critical appraisal of current practice. 2015 , 39, 80-7		17
250	Contemporary antithrombotic strategies in patients with acute coronary syndromes managed without revascularization: insights from the EYESHOT study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015 , 1, 168-78	6.4	19
249	Pretreatment with antiplatelet drugs in invasively managed patients with coronary artery disease in the contemporary era: review of the evidence and practice guidelines. 2015 , 8, e002301		46
248	Adherence to evidence-based secondary prevention pharmacotherapy in patients after an acute coronary syndrome: A systematic review. 2015 , 44, 299-308		27
247	Management of asymptomatic carotid stenosis. 2015 , 33, 443-57		22
246	Clinical utility of new bleeding criteria: a prospective study of evaluation for the Bleeding Academic Research Consortium definition of bleeding in patients undergoing percutaneous coronary intervention. 2015 , 65, 324-9		13
245	Perioperativer Umgang mit moderner Thrombozytenaggregationshemmung. 2015 , 29, 99-111		

244	NSAIDs Hypersensitivity: When and How to Desensitize?. 2015 , 2, 124-140	5
243	Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR . 2015 , 30 Suppl 2, ii1-142	86
242	Evaluating the bioequivalence of clopidogrel generic formulations. 2015 , 31, 861-4	2
241	Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting in the Setting of Acute Coronary Syndrome. 2015 , 116, 148-54	21
240	Impact of prasugrel pretreatment and timing of coronary artery bypass grafting on clinical outcomes of patients with non-ST-segment elevation myocardial infarction: From the A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST-Elevation Myocardial Infarction (ACCOAST) study. 2015 , 170, 1025-1032.e2	14
239	Optimal timing of clopidogrel discontinuation in Japanese patients: platelet aggregation test using the VerifyNow [®] system. 2015 , 63, 601-6	6
238	Preoperative platelet aggregation predicts perioperative blood loss and rethoracotomy for bleeding in patients receiving dual antiplatelet treatment prior to coronary surgery. 2015 , 136, 519-25	18
237	Dual antiplatelet therapy use by Canadian cardiac surgeons. 2015 , 150, 1548-54.e3	16
236	Changes in platelet function independent of pharmacotherapy following coronary intervention in non-ST-elevation myocardial infarction patients. 2015 , 243, 320-7	1
235	4-((R)-2-[[6-((S)-3-Methoxy pyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino]-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester (ACT-246475) and Its Prodrug (ACT-281959), a Novel P2Y ₁₂ Receptor Antagonist with a Wider Therapeutic Window in the Rat Than Clopidogrel. 2015 , 58, 9133-53	32
234	Perioperative management of antiplatelets agents. 2016 , 28, 165-170	
233	When is the Best Time for the Second Antiplatelet Agent in Non-St Elevation Acute Coronary Syndrome?. 2016 , 106, 236-46	3
232	Impact of Implementing a Protocol on the Perioperative Management in Patients Treated with Antithrombotics Admitted for Hip Fracture Surgery: an Observational Study. 2016 , 119, 476-484	1
231	Aspirin before Coronary Artery Surgery. 2016 , 375, 91-2	5
230	Anti-platelet therapy in small animal medicine. 2016 , 39, 318-35	9
229	Outcomes According to Cardiac Catheterization Referral and Clopidogrel Use Among Medicare Patients With Non-ST-Segment Elevation Myocardial Infarction Discharged Without In-hospital Revascularization. 2016 , 5, e002784	3
228	2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2016 , 68, 1082-115	856
227	Response to: Letter to the Editor regarding the manuscript "Symptomatic graft failure and impact on clinical outcome after coronary artery bypass grafting surgery: Results from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease registry". 2016 , 171, e11	

226	American College of Cardiology/American Heart Association 2016 dual antiplatelet therapy (DAPT) focused update: Implications for surgeons. 2016 , 152, 1276-1278	3
225	Results of a single-stage hybrid procedure for patients with coronary and mitral valve disease. 2016 , 209, 328-9	1
224	Do we need P2Y12 inhibitor pretreatment in non-ST elevation acute coronary syndrome?. 2016 , 35, 319-321	
223	Evidence-Based Perioperative Management of Cardiac Medications in Patients Presenting for Noncardiac Surgery. 2016 , 34, 161-180	1
222	2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2016 , 152, 1243-1275	198
221	Preoperative platelet function predicts perioperative bleeding complications in ticagrelor-treated cardiac surgery patients: a prospective observational study. 2016 , 117, 309-15	58
220	Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes. 2016 , 102, 882-92	1
219	Identifying psychosocial predictors of medication non-adherence following acute coronary syndrome: A systematic review and meta-analysis. 2016 , 90, 10-32	40
218	Management of Bleeding Patients. 2016 ,	2
217	Platelet inhibition and bleeding complications in cardiac surgery: A review. 2016 , 50, 349-354	7
216	Early Cessation of Adenosine Diphosphate Receptor Inhibitors Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATE-ACS Study (Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome). 2016 , 9,	15
215	2014 PHA Clinical Practice Guidelines for the Diagnosis and Management of Patients with Coronary Heart Disease. 2016 , 24,	4
214	2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Dis. <i>Circulation</i> , 2016 , 134, e123-55	16.7 737
213	Why we need intravenous antiplatelet agents. 2016 , 12, 553-61	4
212	Do we need P2Y12 inhibitor pretreatment in non-ST elevation acute coronary syndrome?. 2016 , 35, 319-21	
211	New Therapeutic Agents in Thrombosis and Thrombolysis. 2016 ,	6
210	Current status of data on cangrelor. 2016 , 159, 102-9	30
209	Combination of P2Y12 reaction unit and percentage of platelet inhibition assessed by VerifyNow P2Y12 assay is a useful predictor of long-term clinical outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention. 2016 , 139, 114-20	11

208	Secondary Prevention After Symptomatic Large Artery Extracranial Disease. 2016 , 147-160	
207	One-year cardiovascular outcomes of drug-eluting stent versus bare-metal stent implanted in diabetic patients with acute coronary syndrome. 2016 , 79, 239-47	2
206	Cost-Effectiveness Analysis of Ticagrelor and Prasugrel for the Treatment of Acute Coronary Syndrome. 2016 , 9, 22-27	8
205	Impact of preoperative use of P2Y12 receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: A systematic review and meta-analysis. 2017 , 6, 753-770	40
204	Impact of preoperative dual antiplatelet therapy on bleeding complications in patients with acute coronary syndromes who undergo urgent coronary artery bypass grafting. 2017 , 69, 156-161	9
203	Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2°P-TIMI 50 trial. 2017 , 6, 164-172	7
202	Oral Antiplatelet Therapy in Coronary Disease. 2017 , 24, e744-e750	2
201	Dual Antiplatelet Therapy Versus Aspirin Monotherapy in Diabetics With Multivessel Disease Undergoing CABG: FREEDOM Insights. 2017 , 69, 119-127	33
200	Adding CABG to the Dual Antiplatelet Salad. 2017 , 69, 128-130	4
199	Non-ST-Segment Elevation Acute Coronary Syndrome. 2017 , 1-29	1
198	Thrombelastographic hypercoagulability and antiplatelet therapy after coronary artery bypass surgery (TEG-CABG trial): a randomized controlled trial. 2017 , 28, 786-793	20
197	Bleeding associated with the management of acute coronary syndromes. 2017 , 103, 546-562	5
196	Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014. 2017 , 235, 61-66	15
195	Impact of dual antiplatelet therapy after coronary artery bypass surgery on 1-year outcomes in the Arterial Revascularization Trial. 2017 , 52, 456-461	7
194	Regional Anesthesia and Anticoagulation. 2017 , 139-148	
193	The underutilisation of dual antiplatelet therapy in acute coronary syndrome. 2017 , 240, 30-36	11
192	Antithrombotic Therapy to Reduce Ischemic Events in Acute Coronary Syndromes Patients Undergoing Percutaneous Coronary Intervention. 2017 , 6, 131-140	3
191	Cangrelor: Pharmacology, Clinical Data, and Role in Percutaneous Coronary Intervention. 2017 , 6, 39-47	1

190	Updating the Evidence of the Interaction Between Clopidogrel and CYP2C19-Inhibiting Selective Serotonin Reuptake Inhibitors: A Cohort Study and Meta-Analysis. 2017 , 40, 923-932	10
189	Antiplatelet Therapy, Platelet Function Testing, and Bleeding Complications in Cardiac Surgery Patients. 2017 , 43, 699-705	6
188	Contemporary medical therapies of atherosclerotic carotid artery disease. 2017 , 30, 8-16	5
187	Antiplatelet therapy in acute coronary syndrome. 2017 , 3, 11-21	1
186	Antithrombotic Therapy. 2016 , 40, 141-151	1
185	Dual antiplatelet therapy for secondary prevention of coronary artery disease. 2017 , 4, e000651	28
184	Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. 2017 , 70, 1760-1776	100
183	Investigation of standardized administration of anti-platelet drugs and its effect on the prognosis of patients with coronary heart disease. 2017 , 14, 3207-3212	1
182	Precatheterization Use of P2Y Inhibitors in Non-ST-Elevation Myocardial Infarction Patients Undergoing Early Cardiac Catheterization and In-Hospital Coronary Artery Bypass Grafting: Insights From the National Cardiovascular Data Registry. 2017 , 6,	7
181	Clinical outcomes after craniotomy for unruptured intracranial aneurysm in patients with coronary artery disease. 2017 , 46, 113-117	2
180	Antiplatelet therapy with CABG: chaos in the Netherlands. 2017 , 25, 479-480	
179	Benefits and risks of P2Y12 inhibitor preloading in patients with acute coronary syndrome and stable angina. 2017 , 44, 303-315	4
178	Relevance of Indications for CABG in Evaluating the Effect of Dual Antiplatelet Therapy. 2017 , 70, 508	
177	Platelet pathophysiology, pharmacology, and function in coronary artery disease. 2017 , 28, 614-623	10
176	Recognition and Management of Hemostatic Disorders in Critically Ill Patients Needing to Undergo an Invasive Procedure. 2017 , 31, 223-229	5
175	Use of adenosine diphosphate receptor inhibitor prior to left ventricular assist device implantation is not associated with increased bleeding. 2017 , 20, 42-49	2
174	A pharmacotherapy review of the novel, oral antithrombotics. 2017 , 37, 62-70	3
173	Optimizing the Use of Cangrelor in the Real World. 2017 , 17, 5-16	7

172	Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events. 2017 , 12, CD005158	21
171	Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications (Second Edition): Guidelines From the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American	75
170	Clinical pathways and management of antithrombotic therapy in patients with acute coronary syndrome (ACS): a Consensus Document from the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Cardiology (SIC), Italian Society of Emergency Medicine (SIMEU) and Italian Society of Interventional Cardiology (SICI-GISE). 2017 , 19, D130-D150	3
169	Medical Treatment of Intracranial Atherosclerosis: An Update. 2017 , 19, 261-270	22
168	Dual antiplatelet therapy and non-cardiac surgery: evolving issues and anesthetic implications. 2017 , 70, 13-21	14
167	Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting: A Randomized Clinical Trial. 2018 , 319, 1677-1686	94
166	Dual antiplatelet therapy after coronary artery bypass surgery: is there an increase in bleeding risk? A meta-analysis. 2018 , 26, 573-582	3
165	ST-Segment Elevation Myocardial Infarction. 2018 , 311-327	3
164	Early myocardial surgical revascularization after ST-segment elevation myocardial infarction in multivessel coronary disease: bridge therapy is the solution?. 2018 , 19, 120-125	4
163	2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. 2018 , 34, 214-233	125
162	Actualizaci3n ESC 2017 sobre el tratamiento antiagregante plaquetario doble en la enfermedad coronaria, desarrollada en colaboraci3n con la EACTS. 2018 , 71, 42.e1-42.e58	2
161	Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition). 2018 , 43, 263-309	372
160	Impact of ticagrelor versus aspirin on graft patency after CABG: Rationale and design of the TARGET (ticagrelor antiplatelet therapy to reduce graft events and thrombosis) randomized controlled trial (NCT02053909). 2018 , 68, 45-51	6
159	Antiplatelet and Anticoagulant Drugs. 2018 , 303-320	1
158	2017 EACTS Guidelines on perioperative medication in adult cardiac surgery. 2018 , 53, 5-33	183
157	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). 2018 , 39, 213-260	1475
156	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. 2018 , 53, 34-78	149
155	Meta-Analysis of Aspirin Versus Dual Antiplatelet Therapy Following Coronary Artery Bypass Grafting. 2018 , 121, 32-40	23

154	2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery. 2018 , 53, 79-111	165
153	2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery. 2018 , 32, 88-120	155
152	Pattern and predictors of dual antiplatelet use after coronary artery bypass graft surgery. 2018 , 155, 632-638	6
151	Dual antiplatelet therapy post CABG?-perhaps, but why not a radial artery instead?. 2018 , 10, S2106-S2108	2
150	Dual antiplatelet therapy versus aspirin monotherapy in diabetics with stable ischemic heart disease undergoing coronary artery bypass grafting. 2018 , 7, 628-635	3
149	Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis. 2018 , 18, 217	16
148	Acute Myocardial Infarction: STEMI and NSTEMI. 2018 , 123-146	0
147	Is Preoperative Clopidogrel Resistance a Predictor of Bleeding and Risks in Patients Undergoing Emergency CABG Surgery?. 2018 , 33, 330-338	1
146	Effects of tranexamic acid on short-term and long-term outcomes of on-pump coronary artery bypass grafting: Randomized trial and 7-year follow-up. 2018 , 36, e12472	6
145	Use of Antiplatelet Agents in the Neurosurgical Patient. 2018 , 29, 517-527	2
144	Dual versus single antiplatelet therapy after coronary artery bypass graft surgery: An updated meta-analysis. 2018 , 269, 80-88	15
143	Platelet mitochondrial dysfunction and mitochondria-targeted quinone-and hydroquinone-derivatives: Review on new strategy of antiplatelet activity. 2018 , 156, 215-222	10
142	Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease. 2018 , 20, F1-F74	17
141	Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases. 2018 , 70, 526-548	74
140	Role of Platelet Activation and Oxidative Stress in the Evolution of Myocardial Infarction. 2019 , 24, 509-520	16
139	Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions-Part I: Review of Anticoagulation Agents and Clinical Considerations: Endorsed by the Canadian Association of Interventional Radiologists and the Canadian Society of Interventional Radiology	39
138	Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions-Part II: Recommendations: Endorsed by the Canadian Association for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe. 2019 , 30, 1168-1184.e1	156
137	Optimal Duration for Clopidogrel Suspension Prior to Coronary Artery Bypass Grafting. 2019 , 10, 74-82	

136	Perioperative ST-elevation myocardial infarction: with time of the essence, is there a case for guidelines?. 2019 , 123, 548-554	1
135	Endothelial Nitric Oxide Level as a Predictor of Coronary Complexity in Patients With Unstable Angina Pectoris. 2019 , 357, 453-460	4
134	Antiplatelet Therapy and Coronary Artery Bypass Grafting: Analysis of Current Evidence With a Focus on Acute Coronary Syndrome. 2019 , 35, 1030-1038	6
133	Dual antiplatelet therapy in non-ST elevation acute coronary syndromes at Veterans Affairs Hospitals. 2019 , 105, 1575-1582	1
132	Optimization of P2Y Antagonist Ethyl 6-(4-((Benzyloxy)carbamoyl)piperidin-1-yl)-5-cyano-2-methylnicotinate (AZD1283) Led to the Discovery of an Oral Antiplatelet Agent with Improved Druglike Properties. 2019 , 62, 3088-3106	17
131	Antiplatelet Drugs in the Management of Coronary Artery Disease. 2019 , 1017-1029	
130	Endovascular Treatment of Intracranial Atherosclerotic Stenosis. 2019 , 191, 643-652	6
129	Management of Saphenous Vein Graft Disease in Patients with Prior Coronary Artery Bypass Surgery. 2019 , 21, 12	5
128	Comparison of Preventive Cardiovascular Pharmacotherapy in Surgical vs Percutaneous Coronary Revascularization. 2019 , 1, 297-304	
127	Dual antiplatelet therapy up to the time of non-elective coronary artery bypass grafting with prophylactic platelet transfusion: is it safe?. 2019 , 14, 202	3
126	Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use. 2019 , 13, 1753944719893274	38
125	Do We Need Potent Intravenous Antiplatelet Inhibition at the Time of Reperfusion During ST-Segment Elevation Myocardial Infarction?. 2019 , 24, 215-224	4
124	Adjunctive Pharmacologic Therapies in Acute Myocardial Infarction. 2019 , 117-138.e7	1
123	Advances in Antiplatelet and Anticoagulant Therapies for NSTEMI-ACS. <i>Current Cardiology Reports</i> , 2019 , 21, 3	4.2 5
122	Coronary Artery Bypass Grafting Versus Percutaneous Transcatheter Coronary Interventions: Analysis of Outcomes in Myocardial Revascularization. 2019 , 33, 2569-2588	2
121	Surgery and Hemostasis. 2019 , 696-720	
120	Management of bleeding and procedures in patients on antiplatelet therapy. 2020 , 39, 100619	8
119	When is the optimal time to discontinue clopidogrel before in-hospital coronary bypass surgery? A closer look at the current literature. 2020 , 35, 413-421	

118	Synthesis and Biological Evaluation of Thio-Derivatives of 2-Hydroxy-1,4-Naphthoquinone (Lawsonia) as Novel Antiplatelet Agents. 2020 , 8, 533		2
117	Antiplatelet therapy and coronary artery bypass grafting: a systematic review and network meta-analysis. 2020 , 31, 354-363		6
116	Antiplatelet Therapy after Coronary Artery Bypass Graft Surgery, Inconsistency of Clinical Practice and Clinical Significance of Proven Resistance to Antiplatelet Agents. 2020 ,		
115	Effect of ticagrelor with or without aspirin on vein graft outcome 1 year after on-pump and off-pump coronary artery bypass grafting. 2020 , 12, 4915-4923		0
114	Antikoagulation und Thrombozytenaggregationshemmung beim herzchirurgischen Patienten. 2020 , 34, 157-167		
113	Dual Antiplatelet Therapy Duration in Medically Managed Acute Coronary Syndrome Patients: Sub-Analysis of the OPT-CAD Study. <i>Advances in Therapy</i> , 2020 , 37, 3150-3161	4.1	0
112	JCS 2020 Guideline Focused Update on Antithrombotic Therapy in Patients With Coronary Artery Disease. 2020 , 84, 831-865		77
111	Differential effects of dual antiplatelet therapy in patients presented with acute coronary syndrome vs. stable ischaemic heart disease after coronary artery bypass grafting. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, 517-526	6.4	2
110	Hospital Variability Drives Inconsistency in Antiplatelet Use After Coronary Bypass. 2020 , 110, 13-19		2
109	A Novel Index for Prompt Prediction of Severity in Patients with Unstable Angina Pectoris. 2020 , 2020, 7651610		3
108	Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data. 2020 , 20, 724-735		11
107	Preoperative clopidogrel and outcomes in patients with acute coronary syndrome undergoing coronary artery bypass surgery. 2020 ,		6
106	Anticoagulation and antiplatelet therapy post coronary artery bypass surgery. 2021 , 36, 1091-1099		2
105	Antiplatelet Activity of Isorhamnetin via Mitochondrial Regulation. 2021 , 10,		6
104	Impact of provincial and national implementation strategies on P2Y12 inhibitor utilization for acute coronary syndrome in the elderly: an interrupted time series analysis from 2008 to 2018. 2021 , 16, 42		1
103	The relationship between dual antiplatelet treatment (DAPT) score and saphenous venous grafts patency after coronary artery bypass grafting surgery. 2021 , 76, 785-791		1
102	Small bowel ulcer bleeding due to suspected clopidogrel use in a patient with clopidogrel resistance: A case report. 2021 , 9, 3689-3695		0
101	2020 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation. 2021 , 26, 4449		22

100	Dual Antiplatelet Therapy with Clopidogrel and Aspirin Versus Aspirin Monotherapy in Patients Undergoing Coronary Artery Bypass Graft Surgery. 2021 , 10, e020413	2
99	Dual antiplatelet therapy is under-prescribed in patients with surgically treated acute myocardial infarction. 2021 , 33, 687-694	
98	Trends in optimal medical therapy at discharge and clinical outcomes in patients with acute coronary syndrome in Thailand. 2021 , 77, 669-676	1
97	Initiation of and persistence with P2Y12 inhibitors in patients with myocardial infarction according to revascularization strategy: a nationwide study. 2021 , 10, 774-786	
96	Brazilian Society of Cardiology Guidelines on Unstable Angina and Acute Myocardial Infarction without ST-Segment Elevation - 2021. 2021 , 117, 181-264	7
95	Impact of Clopidogrel Stop Interval on Major Adverse Bleeding Events in Cardiac Surgery.. 2022 , 4, 12-19	
94	Comparison of Midterm Outcomes Associated With Aspirin and Ticagrelor vs Aspirin Monotherapy After Coronary Artery Bypass Grafting for Acute Coronary Syndrome. 2021 , 4, e2122597	1
93	The Impact of American College of Cardiology Chest Pain Center Accreditation on Guideline Recommended Acute Myocardial Infarction Management. 2021 , 20, 173-178	
92	Can we think of a TAT, that is a "tailored antiplatelet therapy"?. 2021 , 36, 4805-4807	
91	STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management. 2021 , 35, 2569-2591	8
90	STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management. 2021 , 112, 981-1004	5
89	ST-Segment Elevation Myocardial Infarction. 2022 , 395-411	
88	Percutaneous Image-Guided Interventions Including Solid Organ Biopsies. 2021 , 361-375	
87	Unstable Angina and NonST Elevation Myocardial Infarction. 2012 , 1178-1209	5
86	Surgery and Hemostasis. 2013 , 651-672	1
85	Acute Coronary Syndromes. 2009 , 535-596	9
84	Contemporary antiplatelet therapy in acute coronary syndromes: are there differences in outcomes and discontinuation between clopidogrel and ticagrelor?. 2017 , 47, 1298-1305	12
83	Early Antiplatelet Therapy in Coronary Artery Bypass Grafting a Calculated Benefit. 2010 , 5, 317-325	1

82	Clopidogrel resistance response in patients with coronary artery disease and metabolic syndrome: the role of hyperglycemia and obesity. 2015 , 12, 378-82	9
81	Efficiency of preoperative tranexamic Acid in coronary bypass surgery: an analysis correlated with preoperative clopidogrel use. 2010 , 13, E149-54	6
80	Concurrent Coronary Artery and Valvular Heart Disease - Hybrid Treatment Strategies in 2013. 2013 , 8, 127-130	2
79	Intravenous cangrelor as a peri-procedural bridge with applied uses in ischemic events. 2019 , 7, 408	9
78	Clinical update on the therapeutic use of clopidogrel: treatment of acute ST-segment elevation myocardial infarction (STEMI). 2006 , 2, 379-87	3
77	Early dual antiplatelet therapy versus aspirin monotherapy after coronary artery bypass surgery: survival and safety outcomes. 2020 , 61, 662-672	1
76	Antithrombotic treatment before and after peripheral artery percutaneous angioplasty. 2009 , 7, 18-23	23
75	High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance. 2013 , 3, 23-37	20
74	Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: a consensus document from Italian cardiological, surgical and anaesthesiological societies. 2014 , 10, 38-46	86
73	Incidence, predictors and prognostic importance of bleeding after primary PCI for ST-elevation myocardial infarction. 2010 , 6, 106-111	21
72	Variability of platelet aggregation in patients with clopidogrel treatment and hip fracture: A retrospective case-control study on 112 patients. 2015 , 6, 439-45	8
71	Impact of Clopidogrel Loading for Coronarography on Bleeding After Urgent First Time CABG. 2018 , 72, 319-324	4
70	Cardiac Surgery in Patients with Drug Eluting Stents: The Risk of Stopping Clopidogrel. 2007 , 1, CMC.S340	
69	Traitement de l'infarctus du myocarde avec sus-décalage du segment ST. 2008 , 127-155	
68	CORONARY ARTERY DISEASE. 2009 , 321-365	
67	Three Generations of Thienopyridines: Ticlopidine, Clopidogrel, and Prasugrel. 2009 , 471-484	
66	Design Issues in Clinical Trials of Thrombolytic and Antithrombotic Agents. 2009 , 19-36	
65	Antiplatelet Therapies: Aspirin, Clopidogrel and Thienopyridines, and Glycoprotein IIb/IIIa Inhibitors for the Management of ST-Segment Elevation Myocardial Infarction. 2010 , 219-233	

64 Acute Coronary Syndrome. **2010**, 947-983

63 Manejo de los antiagregantes en el perioperatorio. **2010**, 123-140

62 Antiplatelet Therapy. **2011**, 69-85

61 Revascularization in NonST-Segment Elevation Acute Coronary Syndrome For Whom, When, and How?. **2011**, 299-312

60 Gestes rachidiens et anti-agrégation plaquettaire. **2011**, 267-271

59 Bleeding in the Acute Coronary Syndromes. **2011**, 322-329

58 Anesthesia for Myocardial Revascularization. **2011**, 522-569

1

57 Unstable Angina and Non-ST Elevation Myocardial Infarction. 43-52

56 Anticoagulation Guidelines and Intrathecal Drug Delivery Systems. **2012**, 139-145

55 Preoperative Coronary Intervention. **2012**, 75-84

54 Medical Management of the Patient Undergoing Cardiac Surgery. **2012**, 1793-1810

53 Pharmacogenomics of Cardiovascular Drugs. 98-126

52 Endovascular treatment of extracranial carotid atherosclerotic disease. **2012**, 415-433

51 Platelet ADP P2Y₁₂ Inhibitors: Thienopyridines. 26-46

50 Clopidogrel in ischemic heart disease: A critical appraisal. **2013**, 05, 465-468

49 Linking regional anesthesia and analgesia with postoperative anticoagulation. **2014**, 42-56

48 Antiplatelet Therapy in Patients with Coronary Stent Undergoing Orthopedic Surgery: Is It Still No Man's Land?. **2015**, 41-49

47 Percutaneous Image-Guided Interventions Including Solid Organ Biopsies. **2016**, 281-293

- 46 Clopidogrel use After Myocardial Revascularization: Prevalence, Predictors, and One-Year Survival Rate. **2016**, 31, 106-14 3
- 45 Dual antiplatelet therapy in coronary artery disease. **2018**, 37, 45-50
- 44 Benefits of a combination of clopidogrel and aspirin in patients with high cardiovascular risk. **2019**, 12, 504
- 43 Drug-Drug Interactions in Acute Coronary Syndrome Patients: Systematic Review. **2019**,
- 42 Management of acute coronary syndrome. **2020**, 3626-3655
- 41 Problems of performing coronary artery bypass grafting after preliminary stenting of coronary arteries due to acute coronary syndrome (review of literature). **2020**, 179, 100-106
- 40 Preoperative Assessment of Geriatric Patients Undergoing Elective Intracranial Surgery. **2020**, 12, e12284
- 39 Meta-analysis of Duration of Continuous Dual Antiplatelet Therapy and Late Stent Thrombosis After Second-Generation Drug Stent Implantation. *Advances in Therapy*, **2021**, 38, 1068-1077 4.1
- 38 Antiplatelet Therapy. **2021**, 249-288
- 37 Acute Coronary Syndrome. **2021**, 59-80
- 36 Aortic dissection presenting as acute myocardial infarction: potential harm of antithrombin and antiplatelet therapy. **2006**, 14, 147-149 2
- 35 Balancing potency of platelet inhibition with bleeding risk in the early treatment of acute coronary syndrome. **2009**, 10, 163-75 3
- 34 Coronary revascularization in diabetic patients: Current state of evidence. **2011**, 16, 16-22 13
- 33 A surveillance tool to support quality assurance and research in personalized medicine. **2011**, 2011, 701-8 5
- 32 Evaluation of fibrinolytic medical therapy for patients with acute myocardial infarction. **2012**, 8, 46-9 3
- 31 A novel approach to ischemic mitral regurgitation (IMR). **2015**, 4, 443-8 4
- 30 A randomized controlled trial to assess the efficacy and safety of doubling dose clopidogrel versus ticagrelor for the treatment of acute coronary syndrome in patients with CYP2C19*2 homozygotes. **2015**, 8, 13310-6 6
- 29 A review of antiplatelet drugs, coronary artery diseases and cardiopulmonary bypass. *Journal of Extra-Corporeal Technology*, **2010**, 42, 103-13 0.4

28	Drug-Eluting Stents versus Bare-Metal Stents in Taiwanese Patients with Acute Coronary Syndrome: An Outcome Report of a Multicenter Registry. <i>Acta Cardiologica Sinica</i> , 2014 , 30, 553-64	1.1	10
27	Relationship between maximum clot firmness in ROTEM and postoperative bleeding after coronary artery bypass graft surgery in patients using clopidogrel. <i>Annals of Cardiac Anaesthesia</i> , 2018 , 21, 175-180 ¹³	1.3	2
26	Comparative Review of Oral P2Y Inhibitors. <i>P and T</i> , 2018 , 43, 352-357	1.4	9
25	Dual Antiplatelet Therapy before Coronary Artery Bypass Grafting; a Systematic Review and Meta-Analysis. <i>Archives of Academic Emergency Medicine</i> , 2020 , 8, e61	4.3	1
24	Is the use of dual antiplatelet therapy following urgent and emergency coronary artery bypass surgery associated with increased risk of cardiac tamponade?. <i>Journal of Clinical and Translational Research</i> , 2021 , 7, 229-233	1.1	
23	STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management. <i>Journal of Extra-Corporeal Technology</i> , 2021 , 53, 97-124	0.4	1
22	Eurasian clinical guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndrome (NSTEMI-ACS). <i>Eurasian Heart Journal</i> , 2021 , 6-59	0.7	1
21	Non-ST-Segment Elevation Acute Coronary Syndrome. 2022 , 1-37		
20	Current Perspectives on Antithrombotic Therapy for the Treatment of Acute Coronary Syndrome.. <i>International Journal of General Medicine</i> , 2022 , 15, 2397-2414	2.3	1
19	Antiplatelet Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention.. <i>Current Cardiology Reports</i> , 2022 , 24, 277-293	4.2	0
18	Perioperative Management of P2Y12 Inhibitors in Patients Undergoing Cardiac Surgery within 1 Year of PCI.. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022 ,	6.4	1
17	Risk of bleeding with ticagrelor in elderly patients over 75 years old: A systematic review and meta-analysis. <i>Medicine (United States)</i> , 2021 , 100, e27398	1.8	
16	Comparison of Net Clinical Benefit Between Clopidogrel and Ticagrelor Following Percutaneous Coronary Intervention in Patients in China With Acute Coronary Syndrome.. <i>Advances in Therapy</i> , 2021 , 39, 754	4.1	0
15	Dual antiplatelet therapy before coronary artery bypass grafting in patients with myocardial infarction: a prospective cohort study.. <i>BMC Surgery</i> , 2021 , 21, 449	2.3	
14	Effect of anti-platelet therapy on peri-operative blood loss in patients undergoing off-pump coronary artery bypass grafting.. <i>Annals of Cardiac Anaesthesia</i> , 2022 , 25, 182-187	1.3	
13	Table_1.DOCX. 2020 ,		
12	Part 5: Acute Coronary Syndromes. <i>Circulation</i> , 2005 , 112,	16.7	2
11	Low platelet reactivity in patients with myocardial infarction treated with aspirin plus ticagrelor. <i>Einstein (Sao Paulo, Brazil)</i> , 2022 , 20,	1.2	

10 Monitoring Anticoagulation. **2022**, 417-429

9 Platelet Reactivity and Outcomes after Off-Pump Coronary Surgery in Acute Coronary Syndrome Patients. *Journal of Clinical Medicine*, **2022**, 11, 3285

5-1

8 Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline. **2022**,

3

7 Secretory SERPINE1 Expression Is Increased by Antiplatelet Therapy, Inducing MMP1 Expression and Increasing Colon Cancer Metastasis. **2022**, 23, 9596

0

6 Drug Interactions as a cause of Adverse Drug Reactions in a Tertiary Care Hospital. **2022**, 15, 1637-1645

0

5 Perioperative Management of Antiplatelet Therapy: A Systematic Review and Meta-analysis. **2022**, 6, 564-573

0

4 CYP2C19 genotype and platelet aggregation test-guided dual antiplatelet therapy after off-pump coronary artery bypass grafting: A retrospective cohort study. 9,

0

3 Coronary low-attenuation plaque and high-sensitivity cardiac troponin. *heartjnl-2022-321867*

0

2 Dual or single antiplatelet therapy after coronary surgery for acute coronary syndrome (TACSI trial): Rationale and design of an investigator-initiated, prospective, multinational, registry-based randomized clinical trial. **2023**, 259, 1-8

0

1 Medical Therapy After CABG: the Known Knowns, the Known Unknowns, and the Unknown Unknowns.

0